Provided by Tiger Trade Technology Pte. Ltd.

PTC Therapeutics

66.06
-1.3100-1.94%
Post-market: 66.060.00000.00%19:47 EDT
Volume:792.89K
Turnover:52.68M
Market Cap:5.51B
PE:-108.30
High:68.48
Open:67.80
Low:65.91
Close:67.37
52wk High:90.87
52wk Low:57.74
Shares:83.46M
Float Shares:77.19M
Volume Ratio:0.88
T/O Rate:1.03%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.6100
EPS(LYR):7.78
ROE:-7740.12%
ROA:2.46%
PB:-33.34
PE(LYR):8.49

Loading ...

TD Cowen Upgrades PTC Therapeutics to Buy From Hold, Adjusts Price Target to $90 From $75

MT Newswires Live
·
May 08

Stock Track | PTC Therapeutics Soars 5.57% on Strong Q1 Earnings Beat and Raised Guidance

Stock Track
·
May 08

PTC Therapeutics reports Q1 EPS (3c) vs. ($10.04) last year

TIPRANKS
·
May 08

PTC Therapeutics raises 2026 revenue view to $1.08B-$1.18B, consensus $990.78M

TIPRANKS
·
May 08

GUIDANCE: (PTCT) PTC Therapeutics Expects Full Year 2026 Total Revenue Range $1.08 Billion to $1.18 Billion

MT Newswires Live
·
May 08

Earnings Flash (PTCT) PTC Therapeutics Posts Q1 Loss $0.03 a Share, vs. FactSet Est of $0.47 Loss

MT Newswires Live
·
May 08

PTC Therapeutics Q1 product revenue rises 47%, raises FY guidance

Reuters
·
May 08

PTC Therapeutics Q1 EPS $(0.03) Beats $(0.48) Estimate, Sales $272.551M Beat $218.805M Estimate

Benzinga Earnings
·
May 08

BRIEF-PTC Therapeutics Q1 Net Income USD -2.809 Million

Reuters
·
May 08

PTC Therapeutics Q1 EPS USD -0.03

THOMSON REUTERS
·
May 08

PTC Therapeutics Inc - Raises 2026 Product Revenue Guidance to $750-$850 Mln

THOMSON REUTERS
·
May 08

PTC Therapeutics executives to speak at Bank of America health care conference

Reuters
·
May 04

Earning Preview: PTC Therapeutics this quarter’s revenue is expected to increase by 34.16%, and institutional views are bullish

Earnings Agent
·
Apr 30

Is PTC Therapeutics (PTCT) Pricing Reflect Recent Pipeline Progress And Volatile Share Performance

Simply Wall St.
·
Apr 29

Barclays Keeps Their Buy Rating on PTC Therapeutics (PTCT)

TIPRANKS
·
Apr 29

PTC Therapeutics Reports Positive 24-Month Votoplam Data

TIPRANKS
·
Apr 29

PTC Therapeutics Inc - Votoplam Continues to Show Favorable Safety Profile

THOMSON REUTERS
·
Apr 29

PTC Therapeutics Reports Positive Topline Results From Month 24 Interim Analysis of Pivot-Hd Extension Study of Votoplam

THOMSON REUTERS
·
Apr 29

PTC Therapeutics Inc - Votoplam Shows 52% Slowing of Disease Progression at 10 Mg Dose in Stage 2 Hd

THOMSON REUTERS
·
Apr 29

PTC Therapeutics to report 24-month interim results from PIVOT-HD extension study

Reuters
·
Apr 28